Molecular profiling of multiple myeloma: From gene expression analysis to next-generation sequencing

Luca Agnelli, Pierfrancesco Tassone, Antonino Neri

Research output: Contribution to journalArticle

Abstract

Introduction: Multiple myeloma is a fatal malignant proliferation of clonal bone marrow Ig-secreting plasma cells, characterized by wide clinical, biological, and molecular heterogeneity. Areas covered: Herein, global gene and microRNA expression, genome-wide DNA profilings, and next-generation sequencing technology used to investigate the genomic alterations underlying the bio-clinical heterogeneity in multiple myeloma are discussed. Expert opinion: High-throughput technologies have undoubtedly allowed a better comprehension of the molecular basis of the disease, a fine stratification, and early identification of high-risk patients, and have provided insights toward targeted therapy studies. However, such technologies are at risk of being affected by laboratory-or cohort-specific biases, and are moreover influenced by high number of expected false positives. This aspect has a major weight in myeloma, which is characterized by large molecular heterogeneity. Therefore, meta-analysis as well as multiple approaches are desirable if not mandatory to validate the results obtained, in line with commonly accepted recommendation for tumor diagnostic/prognostic biomarker studies.

Original languageEnglish
JournalExpert Opinion on Biological Therapy
Volume13
Issue numberSUPPL.1
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Multiple Myeloma
Gene expression
Technology
Gene Expression
Genes
DNA Fingerprinting
Expert Testimony
Biomarkers
Plasma Cells
MicroRNAs
Meta-Analysis
Tumors
Bone
Bone Marrow
Throughput
Genome
Plasmas
Weights and Measures
DNA
Neoplasms

Keywords

  • Gene expression profiling
  • MicroRNA
  • Multiple myeloma
  • Next-generation sequencing
  • Noncoding RNA
  • SNP-array genotyping

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Molecular profiling of multiple myeloma : From gene expression analysis to next-generation sequencing. / Agnelli, Luca; Tassone, Pierfrancesco; Neri, Antonino.

In: Expert Opinion on Biological Therapy, Vol. 13, No. SUPPL.1, 06.2013.

Research output: Contribution to journalArticle

@article{0891f2c5cd12442b9a7bb1d165a9577f,
title = "Molecular profiling of multiple myeloma: From gene expression analysis to next-generation sequencing",
abstract = "Introduction: Multiple myeloma is a fatal malignant proliferation of clonal bone marrow Ig-secreting plasma cells, characterized by wide clinical, biological, and molecular heterogeneity. Areas covered: Herein, global gene and microRNA expression, genome-wide DNA profilings, and next-generation sequencing technology used to investigate the genomic alterations underlying the bio-clinical heterogeneity in multiple myeloma are discussed. Expert opinion: High-throughput technologies have undoubtedly allowed a better comprehension of the molecular basis of the disease, a fine stratification, and early identification of high-risk patients, and have provided insights toward targeted therapy studies. However, such technologies are at risk of being affected by laboratory-or cohort-specific biases, and are moreover influenced by high number of expected false positives. This aspect has a major weight in myeloma, which is characterized by large molecular heterogeneity. Therefore, meta-analysis as well as multiple approaches are desirable if not mandatory to validate the results obtained, in line with commonly accepted recommendation for tumor diagnostic/prognostic biomarker studies.",
keywords = "Gene expression profiling, MicroRNA, Multiple myeloma, Next-generation sequencing, Noncoding RNA, SNP-array genotyping",
author = "Luca Agnelli and Pierfrancesco Tassone and Antonino Neri",
year = "2013",
month = "6",
doi = "10.1517/14712598.2013.793305",
language = "English",
volume = "13",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL.1",

}

TY - JOUR

T1 - Molecular profiling of multiple myeloma

T2 - From gene expression analysis to next-generation sequencing

AU - Agnelli, Luca

AU - Tassone, Pierfrancesco

AU - Neri, Antonino

PY - 2013/6

Y1 - 2013/6

N2 - Introduction: Multiple myeloma is a fatal malignant proliferation of clonal bone marrow Ig-secreting plasma cells, characterized by wide clinical, biological, and molecular heterogeneity. Areas covered: Herein, global gene and microRNA expression, genome-wide DNA profilings, and next-generation sequencing technology used to investigate the genomic alterations underlying the bio-clinical heterogeneity in multiple myeloma are discussed. Expert opinion: High-throughput technologies have undoubtedly allowed a better comprehension of the molecular basis of the disease, a fine stratification, and early identification of high-risk patients, and have provided insights toward targeted therapy studies. However, such technologies are at risk of being affected by laboratory-or cohort-specific biases, and are moreover influenced by high number of expected false positives. This aspect has a major weight in myeloma, which is characterized by large molecular heterogeneity. Therefore, meta-analysis as well as multiple approaches are desirable if not mandatory to validate the results obtained, in line with commonly accepted recommendation for tumor diagnostic/prognostic biomarker studies.

AB - Introduction: Multiple myeloma is a fatal malignant proliferation of clonal bone marrow Ig-secreting plasma cells, characterized by wide clinical, biological, and molecular heterogeneity. Areas covered: Herein, global gene and microRNA expression, genome-wide DNA profilings, and next-generation sequencing technology used to investigate the genomic alterations underlying the bio-clinical heterogeneity in multiple myeloma are discussed. Expert opinion: High-throughput technologies have undoubtedly allowed a better comprehension of the molecular basis of the disease, a fine stratification, and early identification of high-risk patients, and have provided insights toward targeted therapy studies. However, such technologies are at risk of being affected by laboratory-or cohort-specific biases, and are moreover influenced by high number of expected false positives. This aspect has a major weight in myeloma, which is characterized by large molecular heterogeneity. Therefore, meta-analysis as well as multiple approaches are desirable if not mandatory to validate the results obtained, in line with commonly accepted recommendation for tumor diagnostic/prognostic biomarker studies.

KW - Gene expression profiling

KW - MicroRNA

KW - Multiple myeloma

KW - Next-generation sequencing

KW - Noncoding RNA

KW - SNP-array genotyping

UR - http://www.scopus.com/inward/record.url?scp=84879569099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879569099&partnerID=8YFLogxK

U2 - 10.1517/14712598.2013.793305

DO - 10.1517/14712598.2013.793305

M3 - Article

C2 - 23614397

AN - SCOPUS:84879569099

VL - 13

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - SUPPL.1

ER -